Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Jun. 2026, Asker Healthcare Group AB has a Sloan Ratio of 8.32%, indicating the company is in the safe zone and there is no funny business with accruals.
Asker Healthcare Group AB (OSTO:ASKER) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, Asker Healthcare Group AB has a Sloan Ratio of 8.32%, indicating the company is in the safe zone and there is no funny business with accruals.
Asker Healthcare Group AB Sloan Ratio % Related Terms
Asker Healthcare Group AB Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ASKER vs MCK, COR, CAH: Sloan Ratio % Comparison
For the Medical Distribution subindustry, Asker Healthcare Group AB's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asker Healthcare Group AB Sloan Ratio % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Asker Healthcare Group AB's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Asker Healthcare Group AB's Sloan Ratio % falls into.
Asker Healthcare Group AB Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Asker Healthcare Group AB's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Asker Healthcare Group AB's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was 142 (Sep. 2025 ) + 130 (Dec. 2025 ) + 193 (Mar. 2026 ) + 219 (Jun. 2026 ) = kr684 Mil.
Asker Healthcare Group AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was 439 (Sep. 2025 ) + 568 (Dec. 2025 ) + 419 (Mar. 2026 ) + 92 (Jun. 2026 ) = kr1,518 Mil.
Asker Healthcare Group AB's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was -974 (Sep. 2025 ) + -657 (Dec. 2025 ) + -265 (Mar. 2026 ) + -422 (Jun. 2026 ) = kr-2,318 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asker Healthcare Group AB (OSTO:ASKER) has a Sloan Ratio % of 8.32% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Asker Healthcare Group AB and its competitors.
Is Asker Healthcare Group AB's Sloan Ratio % too high?
Asker Healthcare Group AB's current Sloan Ratio % is 8.32%. Overall, Asker Healthcare Group AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Asker Healthcare Group AB's Sloan Ratio % compare to MCK and COR?
Asker Healthcare Group AB's Sloan Ratio % of 8.32% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Distribution company?
A good Sloan Ratio % depends on the Medical Distribution industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Asker Healthcare Group AB and its competitors. Asker Healthcare Group AB's current Sloan Ratio % is 8.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asker Healthcare Group AB stock overvalued right now?
Asker Healthcare Group AB (OSTO:ASKER) has a current Sloan Ratio % of 8.32%. The current Sloan Ratio % is 8.32%. Asker Healthcare Group AB's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Asker Healthcare Group AB (OSTO:ASKER), the current Sloan Ratio % is 8.32% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asker Healthcare Group AB is a provider of medical products and solutions that drive progress in the European healthcare sector. The company is engaged in building and acquiring companies to support the healthcare system to improve patient outcomes, reduce the total cost of care, and ensure a fair and sustainable value chain. The company also offers a range of value-added solutions to support its suppliers and customers in, for example, market access, efficiency, and sustainability. Company has adapted a twin engine growth strategy that combines organic and acquired growth. Geographically, the company evaluates the operations in three business areas: North, West and Central.
13GF Score
Get the complete analysis for OSTO:ASKER
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ASKER has been successfully added to your 
